Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the ...
Managed Healthcare Executive10h
High-Dose Eylea Shows Unique Properties in nAMD and DME
A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...
Managed Healthcare Executive13h
High-Dose Eylea Offers Longer Treatment Intervals Across Patient Populations with DME
Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...